Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
Miguel Regueiro(University of Pittsburgh Medical Center), Pierre Desreumaux(Active Biotech (Sweden)), Stephen B. Hanauer(Northwestern University), Harald Vogelsang(Medical University of Vienna), Çharles N. Bernstein(University of Manitoba), Mark J. Ropeleski, Séverine Vermeire(KU Leuven), Olivier Dewit, Richard N. Fedorak(University of Alberta), Peter Bossuyt(Imelda Hospital), Milan Lukáš(Charles University), G. Radford‐Smith(European CanCer Organisation), Denis Franchimont(McGill University Health Centre), Marc Chévrier(Janssen (United States)), William J. Sandborn(University of San Diego), G Reicht, Henry Debinski(Medical University of Vienna), John Popp(Janssen (United States)), Dario Sorrentino(University of Udine), Andrew Sloss, T Haas(Novartis (United States)), B Salh(University of California San Diego), Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), Matthieu Allez(Inserm), Marion Blank(Janssen (United States)), Jean-René Lachance, Geert D’Haens(Amsterdam University Medical Centers), Raymond Bourdages(Centre intégré de santé et de services sociaux de Chaudière-Appalaches), Freddy Cornillie(MSD (Switzerland)), Édouard Louis(Centre Hospitalier Universitaire de Liège), Michael Straßer(Paracelsus Medical University), Paolo Gionchetti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Bin Zou(Janssen (United States)), Paul Rutgeerts(KU Leuven), Ian C. Lawrance(University of Western Australia), Tim Florin(Mater Health Services), Walter Reinisch(Medical University of Vienna), David J. Hetzel(Royal Adelaide Hospital), Sonny S. Dhalla, Scott E. Plevy(Protagonist Therapeutics (United States)), J.F. Colombel, S Gassner, Remo Panaccione(University of Calgary), Jewel Johanns(Janssen (United States)), Naoki Chiba(Surrey Place Centre)
Cited by 329
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Crohn's disease
|The Lancet|2012|2.1k